MED1 knockout mice showed a marked alleviation of hepatic lipid accumulation without affecting other metabolic parameters, suggesting that targeting hepatic MED1 may be a strategy for treating non-alcoholic fatty liver disease (NAFLD) [110]. The gene discussed is MED1; the disease is metabolic dysfunction-associated steatotic liver disease.